Literature DB >> 2967127

Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients.

H F Hoff1, G J Beck, C I Skibinski, G Jürgens, J O'Neil, J Kramer, B Lytle.   

Abstract

Although the serum lipoprotein fraction Lp(a) has been associated with coronary artery atherosclerosis, its relationship to narrowing of saphenous vein grafts has not previously been elucidated. We therefore measured serum Lp(a) levels in 167 symptomatic patients undergoing cardiac catheterization who had had coronary artery bypass surgery 0.7 to 14.3 years earlier. Lp(a), total cholesterol, and total triglyceride levels were compared with the degree of saphenous vein graft stenosis to test for any association. Serum Lp(a) levels were significantly associated with the degree of stenosis of saphenous vein grafts (r = .24, p = .002). Mean Lp(a) levels (mg/dl) in the 135 patients with stenosis were almost double (32.0 +/- 32.7, mean +/- SD) those in the 32 patients with no graft stenosis (16.7 +/- 22.6; p = .002). Graft stenosis was not associated with previous myocardial infarction, hypertension, obesity, diabetes, or smoking. Serum cholesterol levels (mg/dl) were slightly higher in the stenosis group (251.3 +/- 69) than in the no-stenosis group (231.8 +/- 48.8), but the difference was of borderline significance (p = .06). A stepwise increase in mean Lp(a) was found in groups of patients with increasing vein graft stenosis. At a serum Lp(a) level of 31.6 mg/dl or above, 92% of the patients demonstrated vein graft stenosis. Thus, patients with elevated Lp(a) levels have an increased risk of developing saphenous vein graft stenosis after coronary bypass surgery.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2967127     DOI: 10.1161/01.cir.77.6.1238

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  21 in total

1.  Proceedings of the British Pharmacological Society. 12-14 September 1990, Belfast.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

2.  Serum Lp(a) lipoprotein concentration is not associated with clinical and angiographic outcome five years after coronary artery bypass graft surgery.

Authors:  J S Skinner; M Farrer; C J Albers; K Piper; H A Neil; P C Adams
Journal:  Heart       Date:  1997-08       Impact factor: 5.994

Review 3.  Lipoprotein(a): searching for a function.

Authors:  P C Harpel; M Poon; X Zhang; M B Taubman
Journal:  Trans Am Clin Climatol Assoc       Date:  1996

Review 4.  Gonadal hormone substitutes: effects on the cardiovascular system.

Authors:  T B Clarkson; J M Cline; J K Williams; M S Anthony
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

Review 5.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.

Authors:  Børge G Nordestgaard; Anne Langsted
Journal:  J Lipid Res       Date:  2016-09-27       Impact factor: 5.922

6.  Serum LP(A) levels in randomized healthy men from different European countries.

Authors:  M Cigolini; J C Seidell; M G Zenti; G Bonadonna; L Zambelli; J P Deslypere; F Contaldo; A Cruz; J Charzewska; G Targher
Journal:  Eur J Epidemiol       Date:  1993-09       Impact factor: 8.082

Review 7.  Coronary vein graft disease: pathogenesis and prevention.

Authors:  Pirouz Parang; Rohit Arora
Journal:  Can J Cardiol       Date:  2009-02       Impact factor: 5.223

Review 8.  Metabolic syndrome and cardiovascular disease in South Asians.

Authors:  Danny Eapen; Girish L Kalra; Nadya Merchant; Anjali Arora; Bobby V Khan
Journal:  Vasc Health Risk Manag       Date:  2009-09-07

9.  Lipoprotein (a) promotes plasmin inhibition by alpha 2-antiplasmin.

Authors:  J M Edelberg; S V Pizzo
Journal:  Biochem J       Date:  1992-08-15       Impact factor: 3.857

10.  Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein(a) production.

Authors:  D J Rader; W Cain; L A Zech; D Usher; H B Brewer
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.